DILTIAZEM HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Diltiazem Hydrochloride, and when can generic versions of Diltiazem Hydrochloride launch?
Diltiazem Hydrochloride is a drug marketed by Accord Hlthcare, Actavis Elizabeth, Actavis Labs Fl Inc, Amta, Apotex, Biovail, Dr Reddys Labs Sa, Glenmark Pharms Ltd, Mylan, Nesher Pharms, Novast Labs, Par Pharm, Sandoz, Sun Pharm, Teva, Twi Pharms, Valeant Pharms North, Zydus Pharms, Dr Reddys, Eugia Pharma, Hikma Farmaceutica, Hospira, Intl Medication, Mylan Labs Ltd, Rising, Sagent, West-ward Pharms Int, Sciegen Pharms Inc, Apothecon, Chartwell Molecules, Edenbridge Pharms, Ivax Sub Teva Pharms, Teva Pharms, and Exela Pharma. and is included in fifty NDAs.
The generic ingredient in DILTIAZEM HYDROCHLORIDE is diltiazem hydrochloride. There are twenty-six drug master file entries for this compound. Forty-nine suppliers are listed for this compound. Additional details are available on the diltiazem hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Diltiazem Hydrochloride
A generic version of DILTIAZEM HYDROCHLORIDE was approved as diltiazem hydrochloride by TEVA on May 31st, 1995.
Summary for DILTIAZEM HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 34 |
NDAs: | 50 |
Finished Product Suppliers / Packagers: | 43 |
Raw Ingredient (Bulk) Api Vendors: | 131 |
Clinical Trials: | 106 |
Patent Applications: | 2,870 |
Formulation / Manufacturing: | see details |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for DILTIAZEM HYDROCHLORIDE |
What excipients (inactive ingredients) are in DILTIAZEM HYDROCHLORIDE? | DILTIAZEM HYDROCHLORIDE excipients list |
DailyMed Link: | DILTIAZEM HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for DILTIAZEM HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Ascension Genesys Hospital | Phase 2 |
Aurora Health Care | Phase 4 |
Hospices Civils de Lyon | Phase 2 |
Pharmacology for DILTIAZEM HYDROCHLORIDE
Drug Class | Calcium Channel Blocker |
Mechanism of Action | Calcium Channel Antagonists Cytochrome P450 3A4 Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for DILTIAZEM HYDROCHLORIDE
Paragraph IV (Patent) Challenges for DILTIAZEM HYDROCHLORIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
CARDIZEM LA | Extended-release Tablets | diltiazem hydrochloride | 120 mg, 180 mg, 240 mg, 300 mg and 360 mg | 021392 | 1 | 2005-08-30 |
CARDIZEM LA | Extended-release Tablets | diltiazem hydrochloride | 420 mg | 021392 | 1 | 2005-04-25 |
US Patents and Regulatory Information for DILTIAZEM HYDROCHLORIDE
Expired US Patents for DILTIAZEM HYDROCHLORIDE
International Patents for DILTIAZEM HYDROCHLORIDE
See the table below for patents covering DILTIAZEM HYDROCHLORIDE around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Austria | 184196 | ⤷ Try a Trial | |
European Patent Office | 0591424 | DILTIAZEM SE PRESENTANT SOUS UNE FORME A LIBERATION PROLONGEE (EXTENDED-RELEASE FORM OF DILTIAZEM) | ⤷ Try a Trial |
Canada | 2111085 | FORMULATION DE DILTIAZEM A LIBERATION LENTE (EXTENDED-RELEASE FORM OF DILTIAZEM) | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 9300093 | ⤷ Try a Trial | |
Germany | 69229949 | ⤷ Try a Trial | |
Denmark | 0591424 | ⤷ Try a Trial | |
Australia | 2243092 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |